Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study
-
By
-
Zhong Wang
-
Yimin Zhang
-
Feng Yao
-
Jinxin Li
-
Chenyuan Li
-
Shichong Liao
-
June 18, 2026
-
0 min
Top Institutions in Oncology
Brief introduction explaining scope and methodology.
-
#1
Renmin Hospital of Wuhan University
Wuhan, Hubei
-
#2
Wuhan University People’s Hospital
Wuhan, Hubei
-
#3
Dana-Farber Cancer Center
Boston, Massachusetts
-
#4
University of Padua
Padua, Veneto
-
#5
Mayo Clinic
Rochester, Minnesota
